Epizyme (EPZM) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Epizyme (EPZM) Misses Q1 EPS by 3c

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022 7:00 AM EDT

TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021

First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizymes Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL)

Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies

CAMBRIDGE, Mass.--(BUSINESS... More